Targeted therapy and radiation for advanced salivary gland cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a combination of a targeted antibody-drug and focused radiation for people with advanced or recurrent salivary gland cancer that has spread. It aims to see if this treatment can help control the disease when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of salivary gland cancer (like adenoid cystic carcinoma) that has come back or spread, and it shows certain markers (EGFR or TROP2).
- Your cancer has gotten worse after at least one standard treatment, or you are not able to receive standard treatment.
- You have at least one tumor that can be measured on a scan.
- You are generally well enough to be up and about (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and thyroid function are within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called sacituzumab tirumotecan for people with recurrent or metastatic adenoid cystic carcinoma or papillary thyroid carcinoma. The drug works by targeting a protein on cancer cells to deliver treatment directly, which may help shrink tumors or slow their growth.
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
This trial tests a drug called sacituzumab govitecan in people with advanced salivary gland cancer or thyroid cancer that has spread or cannot be removed. The goal is to see if the drug can help shrink or slow down the cancer.
This trial tests whether combining the targeted drug becotatug vedotin with chemo can shrink recurrent adenoid cystic sinus tumors that can't be fully removed by surgery. It's for people whose tumors have a specific protein called EGFR.
This trial studies giving an immunotherapy drug (sintilimab) plus two chemotherapy medicines before surgery to shrink salivary gland cancer. The goal is to improve how well the cancer responds and is controlled, while still aiming for a cure through surgery.
This trial tests an immunotherapy drug (toripalimab) with chemotherapy before surgery for salivary gland cancer. It aims to shrink the tumor to make surgery more effective.
Hear when a new SBRT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.